Photo of Sangharsh Lohakare from Unsplash Investment StrategyAfter decades in biotech, Gimv draws a line under new life sciences dealsBelgian investment company Gimv is drawing a clear line under one chapter of its history. The firm announced via a press release that it will stop making new investments in life sciences and instead … more ➔
ABA AustriaViennaFor €170 million: Vienna gives AI and life sciences a new homeAt a strategy retreat of the city’s political leadership, the governing parties of the City of Vienna agreed to build a new Life Science Center for Vienna – with the new AI institute AITHYRA as its … more ➔
Genmab - Photo Credit: Andrei JackametsClinical trial Genmab pauses enrollment in early ADC trial acquired from ProfoundBioGenmab has stopped enrolling patients in an early-stage clinical trial for an experimental cancer drug it gained through the acquisition of ProfoundBio in April 2024 for €1.52 billion. This pause underscores … more ➔
StatisticsUK retains Europe’s top biotech VC spot despite 2025 slowdownUK biotech is heading into 2026 with a growing sense of momentum, even as the sector continues to navigate one of the most selective investment climates in years. more ➔
LicensingLondon-based Ellipses licenses another oncologic asset from Chinese pharmaThe U.K. biotech Ellipses Pharma, which develops cancer therapeutics, announced a collaboration and licensing agreement with China-based Innolake Biopharm Co. Ltd to develop a clinical-stage, first-in-class … more ➔
Rentschler Biopharma SECDMOBoard reshuffle at RentschlerUnexpected changes at the top of Rentschler Biopharma: CEO Benedikt von Braunmühl and the Supervisory Board agreed on a swift separation in January, and COO Christiane Bardroff is also set to leave … more ➔
RestructuringIO Biotech weighs strategic options months after FDA advises against melanoma vaccine filingFour months after the FDA advised it against filing for approval of its lead melanoma vaccine, IO Biotech is preparing for further restructuring. The Copenhagen-based biotech said yesterday that it is … more ➔
seed fundingOxford-based cancer vaccine company Infinitopes closes $35 million seed roundInfinitopes, a U.K. cancer vaccine biotech spun out of Cancer Research U.K. and the University of Oxford, has expanded its seed round to $35.1 million after a second close that added about $15.4 million … more ➔
TrendsA changing playing field: Observations of the 2026 JP Morgan Healthcare Conference from a European perspectiveThe Westin St. Francis lobby buzzed with its familiar January energy, a peculiar blend of jet lag, ambition, and the faint desperation of biotech CEOs clutching coffee cups like lifelines. This year’s … more ➔
QiagenQiagenTakeover rumours at Qiagen fuel share price surgeWith the departure of the current CEO of diagnostics company Qiagen NV (Venlo, Netherlands/Hilden, Germany) and before a new chief executive has been identified and presented, there appears to be activity … more ➔
Photo of Sangharsh Lohakare from Unsplash 
ABA Austria
Genmab - Photo Credit: Andrei Jackamets
Rentschler Biopharma SE
Qiagen